Candel Therapeutics
CADLCandel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the research and development of novel oncolytic viral immunotherapies designed to treat various forms of cancer. Its approach utilizes modified viruses that are engineered to selectively infect and replicate within tumor cells, with the dual intent of directly lysing those cells and stimulating a systemic, anti-tumor immune response. The company's clinical-stage pipeline is centered on two primary viral immunotherapy platforms. The lead candidate, CAN-2409, is a replication-deficient adenovirus combined with prodrug activation, which is being investigated in multiple solid tumor indications including non-small cell lung cancer, prostate cancer, and pancreatic cancer. A second platform, based on a modified herpes simplex virus (HSV) construct, is represented by CAN-3110, which is in clinical development for recurrent high-grade glioma. These programs are the subject of ongoing Phase 2 and Phase 3 clinical trials to evaluate their safety and efficacy. As a publicly traded entity, Candel Therapeutics operates within the biotechnology and oncology sectors. The company's activities are focused on advancing its clinical programs through the regulatory development pathway, with the goal of generating data to support potential future marketing applications for its investigational cancer therapies.
CADL · Stock Price
Historical price data
About
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the research and development of novel oncolytic viral immunotherapies designed to treat various forms of cancer. Its approach utilizes modified viruses that are engineered to selectively infect and replicate within tumor cells, with the dual intent of directly lysing those cells and stimulating a systemic, anti-tumor immune response. The company's clinical-stage pipeline is centered on two primary viral immunotherapy platforms. The lead candidate, CAN-2409, is a replication-deficient adenovirus combined with prodrug activation, which is being investigated in multiple solid tumor indications including non-small cell lung cancer, prostate cancer, and pancreatic cancer. A second platform, based on a modified herpes simplex virus (HSV) construct, is represented by CAN-3110, which is in clinical development for recurrent high-grade glioma. These programs are the subject of ongoing Phase 2 and Phase 3 clinical trials to evaluate their safety and efficacy. As a publicly traded entity, Candel Therapeutics operates within the biotechnology and oncology sectors. The company's activities are focused on advancing its clinical programs through the regulatory development pathway, with the goal of generating data to support potential future marketing applications for its investigational cancer therapies.